Home/Filings/4/0001209191-23-058977
4//SEC Filing

Alam Kamran 4

Accession 0001209191-23-058977

CIK 0001806310other

Filed

Dec 17, 7:00 PM ET

Accepted

Dec 18, 4:50 PM ET

Size

5.8 KB

Accession

0001209191-23-058977

Insider Transaction Report

Form 4
Period: 2023-12-14
Alam Kamran
CHIEF FINANCIAL OFFICER
Transactions
  • Award

    Employee Stock Option (right to buy)

    2023-12-14+187,582187,582 total
    Exercise: $0.70Exp: 2033-12-14Common Stock (187,582 underlying)
Footnotes (1)
  • [F1]The compensation committee of the board of directors of the Issuer certified achievement of certain performance criteria such that 70% of the option shares subject to the performance-based stock option award were earned. The shares underlying the earned potion of the option shall vest and become exercisable in three equal annual installments commencing on December 31, 2024, subject to the Reporting Person's continuous service through each applicable vesting date.

Issuer

Taysha Gene Therapies, Inc.

CIK 0001806310

Entity typeother

Related Parties

1
  • filerCIK 0001793412

Filing Metadata

Form type
4
Filed
Dec 17, 7:00 PM ET
Accepted
Dec 18, 4:50 PM ET
Size
5.8 KB